MA32027B1 - Preparation de capsules - Google Patents

Preparation de capsules

Info

Publication number
MA32027B1
MA32027B1 MA33030A MA33030A MA32027B1 MA 32027 B1 MA32027 B1 MA 32027B1 MA 33030 A MA33030 A MA 33030A MA 33030 A MA33030 A MA 33030A MA 32027 B1 MA32027 B1 MA 32027B1
Authority
MA
Morocco
Prior art keywords
pharmaceutically active
liquid
solid
capsule
preparation
Prior art date
Application number
MA33030A
Other languages
Arabic (ar)
English (en)
Inventor
Yoshihiro Uchiyama
Tomohiro Yoshinari
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA32027B1 publication Critical patent/MA32027B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur une préparation de capsules contenant des principes pharmaceutiquement actifs liquide et solide, qui a d'excellentes propriétés de libération des principes pharmaceutiquement actifs. De façon spécifique, l'invention porte sur une capsule contenant des principes pharmaceutiquement actifs, liquide et solide, le principe pharmaceutiquement actif liquide étant scellé à l'intérieur de la capsule sous la forme d'une composition pharmaceutique liquide, et le principe pharmaceutiquement actif solide étant dispersé dans une couche de coque de capsule.
MA33030A 2008-01-10 2010-07-16 Preparation de capsules MA32027B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008003634 2008-01-10
PCT/JP2008/073875 WO2009087938A1 (fr) 2008-01-10 2008-12-29 Préparation de capsules

Publications (1)

Publication Number Publication Date
MA32027B1 true MA32027B1 (fr) 2011-01-03

Family

ID=40853060

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33030A MA32027B1 (fr) 2008-01-10 2010-07-16 Preparation de capsules

Country Status (21)

Country Link
US (1) US20100285121A1 (fr)
EP (3) EP2455070A1 (fr)
JP (1) JP5421126B2 (fr)
KR (1) KR20100111292A (fr)
CN (3) CN103705486A (fr)
AU (1) AU2008345848B2 (fr)
BR (1) BRPI0822019A2 (fr)
CA (1) CA2711814A1 (fr)
CO (1) CO6290641A2 (fr)
CR (1) CR11625A (fr)
DO (3) DOP2010000214A (fr)
EA (3) EA201200830A1 (fr)
EC (1) ECSP10010395A (fr)
IL (1) IL206791A0 (fr)
MA (1) MA32027B1 (fr)
MX (1) MX2010007609A (fr)
MY (1) MY157189A (fr)
NZ (3) NZ587019A (fr)
UA (3) UA102477C2 (fr)
WO (1) WO2009087938A1 (fr)
ZA (1) ZA201004793B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028067A1 (fr) 2008-09-02 2010-03-11 Amarin Corporation Plc Composition pharmaceutique comprenant de l'acide eïcosapentaénoïque et de l'acide nicotinique et ses procédés d'utilisation
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
ES2894340T3 (es) 2009-03-09 2022-02-14 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
CN106074486A (zh) 2009-06-15 2016-11-09 阿马里纳药物爱尔兰有限公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl‑c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US9370493B2 (en) * 2009-10-23 2016-06-21 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CA2706270C (fr) * 2010-06-03 2020-01-07 Accucaps Industries Limited Formulations pharmaceutiques de statines et d'acides gras omega-3 pour encapsulation
CA3065589C (fr) * 2010-06-03 2022-04-26 Catalent Ontario Limited Capsules multiphases de gel mou, appareil et procede pour celles-ci
US8609138B2 (en) 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
NZ778131A (en) 2010-11-29 2023-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) * 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
JP5876695B2 (ja) * 2011-09-29 2016-03-02 森下仁丹株式会社 シームレスカプセルおよびその製造方法
EP2775837A4 (fr) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Méthodes de traitement de l'hypertriglycéridémie
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
EP2846779A4 (fr) 2012-05-07 2015-12-16 Omthera Pharmaceuticals Inc Compositions de statines et d'acides gras oméga-3
KR101335365B1 (ko) 2012-05-22 2013-12-02 건일제약 주식회사 오메가-3 지방산 또는 그의 알킬 에스테르 및 스타틴계 약물을 함유하는 다층코팅 형태의 경구투여용 약학 조성물
EP4338805B1 (fr) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Ester éthylique d'acide eicosapentaénoïque destiné à être utilisé dans la réduction du risque d'infarctus myocardique non fatal chez un sujet atteint d'une thérapie par statine
CN102824640A (zh) * 2012-08-06 2012-12-19 济南圣泉唐和唐生物科技有限公司 一种胶囊壳及其制备方法
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014134466A1 (fr) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration d'atorvastatine et d'acide éthyl-eicosapentaénoïque ou d'un dérivé de celui-ci
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20160338948A1 (en) * 2014-01-31 2016-11-24 Morishita Jintan Co., Ltd. Orally administered agent for ruminants and ruminant feed containing same
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (fr) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Procédés de réduction ou de prévention de l'oxydation des ldl petites et denses ou des acides gras polyinsaturés membranaires
CN106659636B (zh) 2014-06-26 2019-10-08 R.P.谢勒技术有限公司 生产封装的颗粒材料的方法、干燥涂层材料的方法以及流化床干燥器
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN104940654A (zh) * 2015-06-24 2015-09-30 黄红林 一种葛根胶囊
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019197961A1 (fr) * 2018-04-09 2019-10-17 Intas Pharmaceuticals Ltd. Composition pharmaceutique d'ésilate de nintédanib
KR20210110890A (ko) 2018-09-24 2021-09-09 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
US12427134B2 (en) 2019-11-12 2025-09-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5488880A (en) * 1977-10-06 1979-07-14 Eru Emu Asoshieito Yuugen Soft capsule
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5953410A (ja) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd 新型ソフトカプセル剤
JPS59157018A (ja) * 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS63238015A (ja) * 1987-03-24 1988-10-04 Morishita Jintan Kk 徐放性カプセル製剤
JPH01186815A (ja) * 1988-01-21 1989-07-26 Tokai Kapuseru Kk 軟カプセル剤およびその製造法
JPH01193216A (ja) * 1988-01-29 1989-08-03 Fuji Kapuseru Kk ソフトカプセル及び球状物
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3159724B2 (ja) * 1991-04-19 2001-04-23 フロイント産業株式会社 シームレスカプセル製造方法および装置
JP3144865B2 (ja) * 1991-12-06 2001-03-12 エーザイ株式会社 軟カプセル剤
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
JPH0823912A (ja) * 1994-07-19 1996-01-30 Yoshinobu Umeda アシタバ入り食品
US5650232A (en) 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
US6531150B1 (en) * 1997-10-30 2003-03-11 Morishita Jintan Co., Ltd. Encapsulated unsaturated fatty acid substance and method for producing the same
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1285651B1 (fr) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Antagonistes de l'hormone concentrant la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
JP5105705B2 (ja) * 2002-05-09 2012-12-26 中外製薬株式会社 光安定化軟カプセル剤
KR100490279B1 (ko) * 2002-07-18 2005-05-17 주식회사 서흥캅셀 구취제거 및 구강 청량 효과를 지닌 젤라틴 연질캅셀제
EP1637134A4 (fr) * 2003-06-20 2010-01-27 Mochida Pharm Co Ltd Composition pour la prevention et le traitement des varices
JP2005046054A (ja) * 2003-07-29 2005-02-24 Nippon Kayaku Co Ltd ダイエット食品及びダイエット用製剤
US20070154541A1 (en) * 2004-04-21 2007-07-05 Kyowa Kakko Kogyo Co., Ltf Seamless capsule containing water-soluble active substance
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1834639B8 (fr) * 2005-01-04 2016-12-07 Mochida Pharmaceutical Co., Ltd. Agent thérapeutique contre la toxicité des graisses
EP1868567A4 (fr) * 2005-03-29 2010-09-29 Mcneil Ppc Inc Compositions contenant des medicaments hydrophiles dans un milieu hydrophobe
AR054368A1 (es) * 2005-06-01 2007-06-20 Takeda Pharmaceutical Metodo para tratar hiperlipidemia
JP4327872B2 (ja) 2005-10-07 2009-09-09 トヨタ自動車株式会社 複数枚の回路基板を固定する固定部材とそれを利用したモジュール
JP4005104B2 (ja) * 2006-02-07 2007-11-07 持田製薬株式会社 脳卒中再発予防用組成物
EP1982710B1 (fr) * 2006-02-07 2013-12-18 Mochida Pharmaceutical Co., Ltd. Composition pour prévenir une récurrence d'accident cardio-vasculaire
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2081550B2 (fr) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
CA2655615A1 (fr) * 2006-06-26 2008-12-17 Valpharma S.A. Composition pharmaceutique destinee a l'administration par voie orale d'acides gras polyinsatures omega et d'au moins un principe actif incompatible avec eux, et procede de preparation de celle-ci
JP5345402B2 (ja) * 2007-01-17 2013-11-20 持田製薬株式会社 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
AU2008272135B2 (en) * 2007-06-29 2013-10-31 Takeda Pharmaceutical Company Limited Seamless capsule

Also Published As

Publication number Publication date
IL206791A0 (en) 2010-12-30
UA102477C2 (en) 2013-07-10
ZA201004793B (en) 2011-09-28
CN103705486A (zh) 2014-04-09
CN103705487A (zh) 2014-04-09
EP2229939A1 (fr) 2010-09-22
MX2010007609A (es) 2010-08-04
CR11625A (es) 2010-09-29
CA2711814A1 (fr) 2009-07-16
DOP2013000085A (es) 2013-06-15
WO2009087938A1 (fr) 2009-07-16
CO6290641A2 (es) 2011-06-20
EP2229939A4 (fr) 2011-04-27
US20100285121A1 (en) 2010-11-11
EA201070835A1 (ru) 2011-02-28
CN101969932A (zh) 2011-02-09
NZ587019A (en) 2012-07-27
JP5421126B2 (ja) 2014-02-19
NZ600721A (en) 2013-03-28
EP2455070A1 (fr) 2012-05-23
JPWO2009087938A1 (ja) 2011-05-26
ECSP10010395A (es) 2010-09-30
DOP2013000087A (es) 2014-01-31
NZ600720A (en) 2012-12-21
UA102478C2 (en) 2013-07-10
EP2455071A1 (fr) 2012-05-23
AU2008345848B2 (en) 2014-05-15
BRPI0822019A2 (pt) 2015-07-21
KR20100111292A (ko) 2010-10-14
UA100403C2 (en) 2012-12-25
DOP2010000214A (es) 2010-07-31
EA201200829A1 (ru) 2012-11-30
MY157189A (en) 2016-05-13
AU2008345848A1 (en) 2009-07-16
EA201200830A1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
MA32027B1 (fr) Preparation de capsules
US8519005B2 (en) Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
MA29681B1 (fr) Formes galeniques du risedronate
MA34296B1 (fr) Composition retard injectable antipsychotique
MA38544A1 (fr) Compositions de principes pharmaceutiques actifs contenant de l'éther de monoéthyle et de diéthylèneglycol ou d'autres dérivés alkyliques
US20110300137A1 (en) Use of lumefantrine and related compounds in the treatment of cancer
TNSN07145A1 (fr) Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
MA33060B1 (fr) Formulations galéniques de composés organiques
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MY160652A (en) Pharmaceutical composition for oral administration
MA33602B1 (fr) Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
EA202000165A1 (ru) ПРОТИВО-PHK ВИРУСНАЯ, В ТОМ ЧИСЛЕ ПРОТИВО-SARS-CoV-2 ВИРУСНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ АВИФАВИР
US20240299382A1 (en) Compounds and methods for degrading rcor1, lsd1, hdac1 and hdac2 in the corest
TR200101928T2 (tr) Geliştirilmiş kararlılığa sahip bileşimler
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
Abd Mutalib et al. Revisiting cyp2c9-mediated drug-drug interactions: A review
NZ596881A (en) Phentermine liquid dosage form
EA200800833A1 (ru) Фармацевтическая липидная композиция в виде частиц
Kaya et al. Severe hyponatremia, epistaxis, and fluoxetine
MA31744B1 (fr) Compositions pharmaceutiques lyophilisees
FR2920308B1 (fr) Forme pharmaceutique pour l'administration par voie orale de principes actifs.
Amponsahа Effect Of 30-Day Administration Of Cellgevityо Supplement On Selected Rat Liver Cytochrome P450 Enzyme Activity And Supplement Interaction With Carbamazepine
TN2010000315A1 (en) Capsule formulation